Supply Chain | August 31, 2024
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Subscribe To Our Newsletter & Stay Updated
